Flagship Harbor Advisors’s Invesco Biotechnology & Genome ETF PBE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $457K | Hold |
5,100
| – | – | 0.02% | 542 |
|
|
2026
Q1 | $404K | Hold |
5,100
| – | – | 0.02% | 524 |
|
|
2025
Q4 | $419K | Hold |
5,100
| – | – | 0.02% | 484 |
|
|
2025
Q3 | $356K | Hold |
5,100
| – | – | 0.02% | 581 |
|
|
2025
Q2 | $327K | Hold |
5,100
| – | – | 0.02% | 580 |
|
|
2025
Q1 | $324K | Hold |
5,100
| – | – | 0.02% | 549 |
|
|
2024
Q4 | $339K | Sell |
5,100
-3,041
| -37% | -$210K | 0.02% | 541 |
|
|
2024
Q3 | $568K | Hold |
8,141
| – | – | 0.03% | 382 |
|
|
2024
Q2 | $528K | Hold |
8,141
| – | – | 0.03% | 389 |
|
|
2024
Q1 | $527K | Hold |
8,141
| – | – | 0.03% | 370 |
|
|
2023
Q4 | $536K | Sell |
8,141
-100
| -1% | -$5.81K | 0.04% | 345 |
|
|
2023
Q3 | $470K | Sell |
8,241
-50
| -0.6% | -$3.05K | 0.04% | 345 |
|
|
2023
Q2 | $508K | Sell |
8,291
-75
| -0.9% | -$4.68K | 0.04% | 331 |
|
|
2023
Q1 | $525K | Sell |
8,366
-275
| -3% | -$17.7K | 0.05% | 341 |
|
|
2022
Q4 | $549K | Hold |
8,641
| – | – | 0.06% | 314 |
|
|
2022
Q3 | $509K | Sell |
8,641
-1,050
| -11% | -$64.7K | 0.06% | 304 |
|
|
2022
Q2 | $560K | Sell |
9,691
-875
| -8% | -$50.4K | 0.06% | 307 |
|
|
2022
Q1 | $655K | Sell |
10,566
-1,615
| -13% | -$98.5K | 0.06% | 296 |
|
|
2021
Q4 | $867K | Buy |
12,181
+315
| +3% | +$22.8K | 0.08% | 252 |
|
|
2021
Q3 | $918K | Hold |
11,866
| – | – | 0.1% | 220 |
|
|
2021
Q2 | $918K | Sell |
11,866
-185
| -2% | -$13.7K | 0.1% | 221 |
|
|
2021
Q1 | $890K | Buy |
12,051
+500
| +4% | +$37.8K | 0.1% | 219 |
|
|
2020
Q4 | $810K | Sell |
11,551
-75
| -0.6% | -$4.75K | 0.1% | 217 |
|
|
2020
Q3 | $658K | Buy |
11,626
+2,385
| +26% | +$140K | 0.09% | 217 |
|
|
2020
Q2 | $538K | Buy |
9,241
+1,100
| +14% | +$59.9K | 0.08% | 240 |
|
|
2020
Q1 | $379K | Hold |
8,141
| – | – | 0.08% | 250 |
|
|
2019
Q4 | $455K | Hold |
8,141
| – | – | 0.08% | 248 |
|
|
2019
Q3 | $385K | Hold |
8,141
| – | – | 0.08% | 264 |
|
|
2019
Q2 | $435K | Hold |
8,141
| – | – | 0.09% | 229 |
|
|
2019
Q1 | $449K | Hold |
8,141
| – | – | 0.09% | 232 |
|
|
2018
Q4 | $383K | Hold |
8,141
| – | – | 0.09% | 231 |
|
|
2018
Q3 | $478K | Hold |
8,141
| – | – | 0.09% | 239 |
|
|
2018
Q2 | $445K | Hold |
8,141
| – | – | 0.09% | 238 |
|
|
2018
Q1 | $383K | Hold |
8,141
| – | – | 0.11% | 212 |
|
|
2017
Q4 | $393K | Hold |
8,141
| – | – | 0.11% | 208 |
|
|
2017
Q3 | $408K | Hold |
8,141
| – | – | 0.13% | 193 |
|
|
2017
Q2 | $373K | Hold |
8,141
| – | – | 0.13% | 193 |
|
|
2017
Q1 | $335K | Hold |
8,141
| – | – | 0.13% | 199 |
|
|
2016
Q4 | $324K | Buy |
+8,141
| New | +$329K | 0.14% | 183 |
|
Other funds holding PBE
UCFA
GKWIM
YIA
Flagship Harbor Advisors's PBE Position: Q2 2026 in Review
Flagship Harbor Advisors held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q2 2026 at 5,100 shares worth $457K. The position accounts for 0.02% of the portfolio, ranked #542.
Flagship Harbor Advisors first reported a position in PBE in Q4 2016 and has held it in 39 quarters since. The position peaked at $918K in Q3 2021. 105 funds tracked by Wall St. Rank hold PBE as of Q2 2026.
- Flagship Harbor Advisors held 5,100 shares of Invesco Biotechnology & Genome ETF worth $457K as of Q2 2026.
- Flagship Harbor Advisors left its Invesco Biotechnology & Genome ETF share count unchanged in Q2 2026.
- Invesco Biotechnology & Genome ETF made up 0.02% of Flagship Harbor Advisors's portfolio in Q2 2026, its #542 holding.
- Flagship Harbor Advisors first reported a position in Invesco Biotechnology & Genome ETF in Q4 2016 and has held it in 39 quarters since.
- Flagship Harbor Advisors's Invesco Biotechnology & Genome ETF position peaked at $918K in Q3 2021.
- 105 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2026.
Based on Flagship Harbor Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.